Loading study record…
INTERVENTIONALCOMPLETEDNCT00711646
A Double Blind, Randomised, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Cannabis Based Medicine 1:1 THC:CBD Compared With Placebo for the Treatment of Spasticity in Patients With Multiple Sclerosis.
The purpose of this study is to evaluate the efficacy, safety and tolerability of Sativex® in subjects diagnosed with MS and spasticity.
Locally preserved from ClinicalTrials.govOpen ClinicalTrials.gov↗last source update 2023-05-06
What this record can show
Registry results are available
Results are reported by the registry submitter and preserved exactly. They are not independent verification or a treatment recommendation.
Registry facts
Study at a glance
- Phase
- PHASE3
- Enrollment
- 189 (ACTUAL)
- Start date
- 2002-06
- Sponsor
- Jazz Pharmaceuticals
- Design
- RANDOMIZED · PARALLEL · SUPPORTIVE CARE
- Locations
- 1
- Results record
- Present in registry snapshot
This was an eight week (two weeks baseline, six weeks treatment), multicentre, double blind, randomised, placebo controlled parallel group study to evaluate the efficacy, safety and tolerability of Sativex® in subjects diagnosed with MS and spasticity. Subjects were screened to determine eligibility and completed a two week baseline period. Subjects then returned to the site for assessment, randomisation and dose introduction. Visits occurred at the end of treatment week two and at the end of the study (treatment week six) or withdrawal.
SpasticityMultiple SclerosisSpasticityMultiple Sclerosis
Linked local records
Related local records
Local links use governed condition terms or exact source-reported intervention names. They are navigation candidates, not efficacy claims.
Cannabinoids and active compounds
No governed compound link was found.
Interventions
What was registered
DRUGSativex®
containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
GW-1000-02DRUGPlacebo
containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
GW-4001-01 Source-reported results
Results posted to the registry
7 outcomesResults are reported by the registry submitter and preserved exactly. They are not independent verification or a treatment recommendation.
- Primary outcomes
- 1
- Secondary outcomes
- 6
- Statistical analyses
- 6
- Adverse-event terms
- 29
PRIMARYAssessment of Change From Baseline in the Mean Spasticity 0-10 Numerical Rating Scale Score.
- Time frame
- 0-52 days
- Measure
- MEAN · units on a scale
- Reporting status
- POSTED
The spasticity Numerical Rating Scale was completed at the same time each day, i.e. bedtime in the evening. The patient was asked "on a scale of '0 to 10', please indicate the number that best describes your average spasticity in the last 24 hours" where 0 = no spasticity and 10 = worst ever spasticity. For the analysis, end of treatment was defined as the mean of the last seven days in the study or the last three days if the subject withdrew due to worsening spasticity or lack of efficacy. A negative value indicates an improvement in spasticity score from baseline.
Population: All randomised subjects who received at least one dose of study medication and had on-treatment efficacy data were included in the analysis.
| Group | N | Value | Spread / interval |
|---|
| Sativex | 120 | -1.18 | 1.83 |
| Placebo | 64 | -0.63 | 1.62 |
Statistical analyses
Sativex vs PlaceboANCOVAEstimated mean treatment difference: -0.517p-value: 0.04895% CI · -1.029 · -0.004SECONDARYChange From Baseline in Mean Ashworth Scale Score at the End of Treatment
- Time frame
- Days 0 - 52
- Measure
- MEAN · units on a scale
Eligibility
Population and criteria
- Sex
- ALL
- Minimum age
- 18 Years
- Maximum age
- Not reported
- Healthy volunteers
- Not accepted
Inclusion criteria
- Willing and able to give informed consent.
- Male or female, aged 18 years or above.
- Stable disease for at least three months prior to study entry, in the opinion of the investigator.
- Diagnosed with MS whose spasticity was not wholly relieved with the therapy at the time of study entry.
- Significant spasticity in at least two muscle groups defined as a score of two or more on the Ashworth Scale for each muscle group.
- Stable dose of current anti-spasticity medication for at least 30 days prior to study entry.
- Willing to maintain a stable dose of anti-spasticity medication and level of physiotherapy for the duration of the study.
- Clinically acceptable laboratory results at Visit 2.
- Willing, if female and of child bearing potential or male subjects with a partner of child bearing potential, to ensure that effective contraception was used during the study and for three months thereafter.
- No cannabinoid use (cannabis, Marinol® or Nabilone) for at least seven days before Visit 1 and were willing to abstain from any use of cannabis during the study.
- Able (in the investigators opinion) and willing to comply with all study requirements.
- Willing for the Home Office to be notified of his or her participation in the study (applicable to the UK centres only).
- Willing to allow his or her GP and consultant, if appropriate, to be notified of participation in the study.
Exclusion criteria
- History of schizophrenia, other psychotic illness, severe personality disorder or other significant psychiatric disorder other than depression associated with their underlying condition.
- Known history of alcohol or substance abuse.
- Severe cardiovascular disorder, such as ischaemic heart disease, arrhythmias, poorly controlled hypertension or severe heart failure.
- History of epilepsy.
- Female subject who was pregnant, lactating or planning pregnancy during the course of the study.
- Significant renal or hepatic impairment.
- Scheduled elective surgery or other procedures requiring general anaesthesia during the study.
primary outcomes
primary measures
Assessment of Change From Baseline in the Mean Spasticity 0-10 Numerical Rating Scale Score.
Time frame: 0-52 days
The spasticity Numerical Rating Scale was completed at the same time each day, i.e. bedtime in the evening. The patient was asked "on a scale of '0 to 10', please indicate the number that best describes your average spasticity in the last 24 hours" where 0 = no spasticity and 10 = worst ever spasticity. For the analysis, end of treatment was defined as the mean of the last seven days in the study or the last three days if the subject withdrew due to worsening spasticity or lack of efficacy. A negative value indicates an improvement in spasticity score from baseline.
secondary outcomes
secondary measures
Change From Baseline in Mean Ashworth Scale Score at the End of Treatment
Time frame: Days 0 - 52
The mean Ashworth Scale score across muscle groups was calculated using only those muscle groups with a score of greater than or equal to two at baseline. All 20 muscle groups were assessed for spasticity (using a 1-5 scale): 1= no increase in muscle tone to 5= passive movement is difficult and affected part is rigid in flexion or extension. The score for all 20 muscle groups were added to give a total score out of 100; minimum score was 20. A decrease in score indicates an improvement in condition.
Change From Baseline in Mean Spasm Frequency Score at the End of Treatment
Time frame: Days 0 - 52
Each day subjects recorded in their diary the frequency of their spasms using the following scoring system: 0 = no spasms, 1 = one or fewer spasms per day, 2 = between one and five spasms per day, 3 = six to nine spasms per day, 4 = ten or more spasms per day or continuous contraction. For the analysis, end of treatment was defined as the mean of the last seven days in the study or the last three days if the subject withdrew due to worsening spasticity or lack of efficacy.
Change From Baseline in Mean Motricity Index Score for the Arms
Time frame: Day 7 and 52
Arm - 3 movements were pinch grip, elbow flexion and shoulder abduction. The total arm score was the addition of the score for the 3 arm movements. One point was then added to give a maximum score of 100; minimum was 1 point. Where both arms were assessed, the average of the two limbs scores was used as the assessment score; otherwise the affected limb total score was used. An increase in score indicates an improvement in condition..
Patient's Global Impression of Change in Condition at the End of Treatment
Time frame: Day 52
A 7-point Likert-type scale was used, with the question: 'Please assess the change in your condition since entry into the study using the scale below' with the markers "very much improved, much improved, slightly improved, no change, slightly worse, much worse or very much worse". At Visit 2 (Baseline) patients wrote a brief description of their condition which was used at end of treatment to aid their memory regarding their symptoms at study start. For each of above markers the number of participants were reported.
Incidence of Adverse Events as a Measure of Subject Safety
Publications
Locally readable linked articles
0No exact PMID-linked public article is currently readable locally.
Snapshot provenance
- Snapshot
- 8d6ec5bd-f1bf-45c8-873a-e8b97a28974c
- Retrieved
- 11/09/2026, 14:54:39
- SHA-256
- a745d2af5371d5fcf7cba9b4f19aeba83c240a2778b7312dde79cab6f3b9f912
The mean Ashworth Scale score across muscle groups was calculated using only those muscle groups with a score of greater than or equal to two at baseline. All 20 muscle groups were assessed for spasticity (using a 1-5 scale): 1= no increase in muscle tone to 5= passive movement is difficult and affected part is rigid in flexion or extension. The score for all 20 muscle groups were added to give a total score out of 100; minimum score was 20. A decrease in score indicates an improvement in condition.
Population: All randomised subjects who received at least one dose of study medication and had on-treatment efficacy data were included in the analysis.
| Group | N | Value | Spread / interval |
|---|
| Sativex | 114 | -0.64 | 0.56 |
| Placebo | 63 | -0.53 | 0.58 |
Statistical analyses
Sativex vs PlaceboANCOVAEstimated mean treatment difference: -0.11p-value: 0.21895% CI · -0.29 · 0.07SECONDARYChange From Baseline in Mean Spasm Frequency Score at the End of Treatment
- Time frame
- Days 0 - 52
- Measure
- MEAN · units on a scale
- Reporting status
- POSTED
Each day subjects recorded in their diary the frequency of their spasms using the following scoring system: 0 = no spasms, 1 = one or fewer spasms per day, 2 = between one and five spasms per day, 3 = six to nine spasms per day, 4 = ten or more spasms per day or continuous contraction. For the analysis, end of treatment was defined as the mean of the last seven days in the study or the last three days if the subject withdrew due to worsening spasticity or lack of efficacy.
| Group | N | Value | Spread / interval |
|---|
| Sativex | 120 | -0.37 | 0.77 |
| Placebo | 64 | -0.26 | 0.74 |
Statistical analyses
Sativex vs PlaceboANCOVAEstimated mean treatment difference: -0.17p-value: 0.14195% CI · -0.39 · 0.06SECONDARYChange From Baseline in Mean Motricity Index Score for the Arms
- Time frame
- Day 7 and 52
- Measure
- MEAN · units on a scale
- Reporting status
- POSTED
Arm - 3 movements were pinch grip, elbow flexion and shoulder abduction. The total arm score was the addition of the score for the 3 arm movements. One point was then added to give a maximum score of 100; minimum was 1 point. Where both arms were assessed, the average of the two limbs scores was used as the assessment score; otherwise the affected limb total score was used. An increase in score indicates an improvement in condition..
Population: All randomised subjects who received at least one dose of study medication and had on-treatment efficacy data were included in the analysis.
| Group | N | Value | Spread / interval |
|---|
| Sativex | 25 | 3.64 | 14.82 |
| Placebo | 15 | 3.07 | 10.08 |
Statistical analyses
Sativex vs PlaceboANCOVAEstimated mean treatment difference: 1.30p-value: 0.76695% CI · -7.47 · 10.07SECONDARYPatient's Global Impression of Change in Condition at the End of Treatment
- Time frame
- Day 52
- Measure
- NUMBER · participants
- Reporting status
- POSTED
A 7-point Likert-type scale was used, with the question: 'Please assess the change in your condition since entry into the study using the scale below' with the markers "very much improved, much improved, slightly improved, no change, slightly worse, much worse or very much worse". At Visit 2 (Baseline) patients wrote a brief description of their condition which was used at end of treatment to aid their memory regarding their symptoms at study start. For each of above markers the number of participants were reported.
Population: All randomised subjects who received at least one dose of study medication and had on-treatment efficacy data were included in the analysis.
| Group | N | Value | Spread / interval |
|---|
| Sativex | 124 | 2 | - |
| Placebo | 65 | 0 | - |
| Sativex | 124 | 24 | - |
| Placebo | 65 | 11 | - |
| Sativex | 124 | 40 | - |
| Placebo | 65 | 20 | - |
| Sativex | 124 | 38 | - |
| Placebo | 65 | 26 | - |
| Sativex | 124 | 10 | - |
| Placebo | 65 | 5 | - |
| Sativex | 124 | 2 | - |
| Placebo | 65 | 2 | - |
| Sativex | 124 | 0 | - |
| Placebo | 65 | 0 | - |
| Sativex | 124 | 8 | - |
| Placebo | 65 | 1 | - |
Statistical analyses
Sativex vs PlaceboFisher ExactEstimated mean treatment difference: 8.46p-value: 0.34995% CI · -6.74 · 23.66SECONDARYIncidence of Adverse Events as a Measure of Subject Safety
- Time frame
- Day 0-52
- Measure
- NUMBER · participants
- Reporting status
- POSTED
The number of subjects who reported an adverse event during the course of the study is presented.
Population: All randomised subjects who received at least one dose of study medication and had on-treatment efficacy data were included in the analysis.
| Group | N | Value | Spread / interval |
|---|
| Sativex | 124 | 102 | - |
| Placebo | 65 | 46 | - |
SECONDARYChange From Baseline in Mean Motricity Index Score for the Legs
- Time frame
- Day 7 and Day 52
- Measure
- MEAN · units on a scale
- Reporting status
- POSTED
Ankle dorsiflexion, knee extension and hip flexion were assessed and scored to give a maximum of 100%. The Motricity Index score (scale 1-100) was recorded for limbs that had an associated Ashworth Scale score, which was greater than or equal to two at baseline.
Population: All randomised subjects who received at least one dose of study medication and had on-treatment efficacy data were included in the analysis.
| Group | N | Value | Spread / interval |
|---|
| Sativex | 103 | 6.01 | 12.30 |
| Placebo | 56 | 2.15 | 13.41 |
Statistical analyses
Sativex vs PlaceboANCOVAEstimated mean treatment difference: 3.86p-value: 0.05495% CI · -0.06 · 7.78Participant flow1 period
Overall Study
| Milestone | Sativex | Placebo |
|---|
| STARTED | 124 | 65 |
| COMPLETED | 112 | 62 |
| NOT COMPLETED | 12 | 3 |
Why participants did not complete
- Adverse Event: Sativex 6 · Placebo 1
- Withdrawal by Subject: Sativex 4 · Placebo 0
- Protocol Violation: Sativex 0 · Placebo 1
- Lost to Follow-up: Sativex 1 · Placebo 0
- administrative decision: Sativex 0 · Placebo 1
- patient non-compliance: Sativex 1 · Placebo 0
Baseline4 measures
Age, Categorical
COUNT_OF_PARTICIPANTS · Participants- Sativex: 0
- Placebo: 0
- Total: 0
- Sativex: 118
- Placebo: 65
- Total: 183
- Sativex: 6
- Placebo: 0
- Total: 6
Age, Continuous
MEAN · years- Sativex: 49.7 ± 10.2
- Placebo: 47.8 ± 9.5
- Total: 49.1 ± 9.9
Sex: Female, Male
COUNT_OF_PARTICIPANTS · Participants- Sativex: 80
- Placebo: 34
- Total: 114
- Sativex: 44
- Placebo: 31
- Total: 75
Region of Enrollment
NUMBER · participants- Sativex: 108
- Placebo: 56
- Total: 164
- Sativex: 16
- Placebo: 9
- Total: 25
SafetyAdverse events reported
Sativex
Serious: 4 / 124Other: 102 / 124Placebo
Serious: 3 / 65Other: 46 / 65Serious adverse-event terms (9)
| Event | System | Groups: affected / at risk |
|---|
| Vomiting NOS | Gastrointestinal disorders | Sativex: 1 / 124 · Placebo: 0 / 65 |
| Appendicitis | Gastrointestinal disorders | Sativex: 0 / 124 · Placebo: 1 / 65 |
| Mobility Decreased | General disorders | Sativex: 1 / 124 · Placebo: 0 / 65 |
| Bartholin's Abscess | Infections and infestations | Sativex: 1 / 124 · Placebo: 0 / 65 |
| Urinary Tract Infection NOS | Infections and infestations | Sativex: 2 / 124 · Placebo: 1 / 65 |
| Lower Respiratory Tract Infection NOS | Infections and infestations | Sativex: 0 / 124 · Placebo: 1 / 65 |
| Pancreatic Carcinoma NOS | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Sativex: 1 / 124 · Placebo: 0 / 65 |
| Urinary Incontinence Aggravated | Renal and urinary disorders | Sativex: 1 / 124 · Placebo: 0 / 65 |
| Pulmonary Embolism | Respiratory, thoracic and mediastinal disorders | Sativex: 0 / 124 · Placebo: 1 / 65 |
Other adverse-event terms (20)
| Event | System | Groups: affected / at risk |
|---|
| Dizziness | Nervous system disorders | Sativex: 40 / 124 · Placebo: 7 / 65 |
| Fatigue | General disorders | Sativex: 13 / 124 · Placebo: 4 / 65 |
| Urinary Tract Infection NOS | Infections and infestations | Sativex: 13 / 124 · Placebo: 6 / 65 |
| Dry Mouth | Gastrointestinal disorders | Sativex: 11 / 124 · Placebo: 4 / 65 |
| Balance Impaired NOS | Nervous system disorders | Sativex: 9 / 124 · Placebo: 1 / 65 |
| Nausea | Gastrointestinal disorders | Sativex: 9 / 124 · Placebo: 4 / 65 |
| Headache NOS | Nervous system disorders | Sativex: 8 / 124 · Placebo: 4 / 65 |
| Diarrhoea NOS | Gastrointestinal disorders | Sativex: 7 / 124 · Placebo: 2 / 65 |
| Oral Pain | Gastrointestinal disorders | Sativex: 6 / 124 · Placebo: 7 / 65 |
| Somnolence | Nervous system disorders | Sativex: 6 / 124 · Placebo: 1 / 65 |
| Confusion | Psychiatric disorders | Sativex: 6 / 124 · Placebo: 2 / 65 |
| Depressed Mood | Psychiatric disorders | Sativex: 6 / 124 · Placebo: 0 / 65 |
| Constipation | Gastrointestinal disorders | Sativex: 5 / 124 · Placebo: 1 / 65 |
| Disorientation | Psychiatric disorders | Sativex: 5 / 124 · Placebo: 1 / 65 |
| Dysgeusia | Nervous system disorders | Sativex: 5 / 124 · Placebo: 1 / 65 |
| Disturbance in Attention | Nervous system disorders | Sativex: 4 / 124 · Placebo: 0 / 65 |
| Euphoric mood | Psychiatric disorders | Sativex: 4 / 124 · Placebo: 2 / 65 |
| Vision Blurred | Eye disorders | Sativex: 4 / 124 · Placebo: 0 / 65 |
| Weakness | General disorders | Sativex: 4 / 124 · Placebo: 1 / 65 |
| Pain in Limb | Musculoskeletal and connective tissue disorders | Sativex: 4 / 124 · Placebo: 1 / 65 |
Subject who was terminally ill or was inappropriate for placebo medication.Any other significant disease or disorder which, in the opinion of the investigator, either put the subject at risk because of participation in the study, or influenced the result of the study, or the subject's ability to participate in the study.Regular levodopa (Sinemet®, Sinemet Plus®, Levodopa, L-dopa, Madopar®, Benserazide) therapy within seven days of study entry.Male subject receiving sildenafil (Viagra®) and unwilling to stop medication for the duration of the study.Subjects who were taking fentanyl (Durogesic®, Actiq®)Subjects who were taking antiarrhythmic medications.Known or suspected hypersensitivity to cannabinoids or any of the excipients of the study medications.Known or suspected adverse reaction to cannabinoids.Planned travel outside the UK during the study (applicable to the UK centres only).Donation of blood during the study.Subjects who had participated in another research study in the 12 weeks prior to study entry.Subjects previously randomised into this study.The number of subjects who reported an adverse event during the course of the study is presented.
Change From Baseline in Mean Motricity Index Score for the Legs
Time frame: Day 7 and Day 52
Ankle dorsiflexion, knee extension and hip flexion were assessed and scored to give a maximum of 100%. The Motricity Index score (scale 1-100) was recorded for limbs that had an associated Ashworth Scale score, which was greater than or equal to two at baseline.
A Double Blind, Randomised, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Cannabis Based Medicine 1:1 THC:CBD Compared With Placebo for the Treatment of Spasticity in Patients With Multiple Sclerosis. - Medical Cannabis Research Engine